查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178056

抗放射線藥的全球市場:各化合物(碘化鉀，布魯士藍，DTPA，其他)-產業分析，市場規模，佔有率，成長，趨勢，預測(2022年～2031年)

Anti-radiation Drugs Market (Compound: Potassium Iodide, Prussian Blue, DTPA, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 213 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球抗放射線藥市場相關調查分析，提供市場概要，市場分析，競爭情形等系統性資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球抗放射線藥市場

第4章 市場概要

  • 簡介
    • 定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球抗放射線藥市場分析與預測(2017年～2031年)

第5章 主要洞察

  • 開發平台分析
  • 主要的產業活動(夥伴關係，投資，M&A等)
  • 放射治療藥相關洞察
  • 法規情勢:主要各區各國
  • COVID-19影響分析

第6章 全球抗放射線藥市場分析與預測:各化合物

  • 簡介和定義
  • 市場金額的預測(2017年～2031年):各化合物
    • 碘化鉀(KI)
    • 布魯士藍
    • DTPA(二乙烯三胺五乙酸酯)
    • 其他
  • 市場魅力:各化合物

第7章 全球抗放射線藥市場分析與預測:各用途

  • 簡介和定義
  • 市場金額預測(2017年～2031年):各用途
    • 急性輻射症候群(ARS)
    • 癌症治療
    • 放射線被炸
    • 其他
  • 市場魅力分析:各用途

第8章 全球抗放射線藥市場分析與預測:各流通管道

  • 簡介和定義
  • 市場金額預測(2017年～2031年):各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 市場魅力分析:各流通管道

第9章 全球抗放射線藥市場分析與預測:各地區

  • 主要調查結果
  • 市場金額預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第10章 北美的抗放射線藥市場分析與預測

第11章 歐洲的抗放射線藥市場分析與預測

第12章 亞太地區的抗放射線藥市場分析與預測

第13章 南美的抗放射線藥市場分析與預測

第14章 中東及非洲的抗放射線藥市場分析與預測

第15章 競爭情形

  • 市場參與企業-競爭矩陣(各等級及各企業規模)
  • 市場佔有率分析(2021年):各企業
  • 企業簡介
    • Amgen Inc.
    • Anbex Inc.
    • Arco Pharmaceuticals LLC
    • BTG International Inc.
    • Cellphire, Inc.
    • Chrysalis BioTherapeutics, Inc.
    • Darnitsa
    • Enzychem Lifesciences Corporation
    • Humanetics Corporation
    • Mission Pharmacal Company
    • Myelo Therapeutics GmbH
    • Partner Therapeutics
    • Pluri Inc.
    • 其他
Product Code: TMRGL85240

TMR's report on the global anti-radiation drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anti-radiation drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-radiation drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anti-radiation drugs market.

The report delves into the competitive landscape of the global anti-radiation drugs market. Key players operating in the global anti-radiation drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anti-radiation drugs market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anti-radiation Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anti-radiation Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Industry Events (Partnership, Investment, Merger & Acquisition, etc.)
  • 5.3. Insights on Radiation Pills
  • 5.4. Regulatory Scenario, by Key Region/ Country
  • 5.5. COVID-19 Impact Analysis

6. Global Anti-radiation Drugs Market Analysis and Forecast, by Compound

  • 6.1. Introduction & Definition
  • 6.2. Market Value Forecast, by Compound, 2017-2031
    • 6.2.1. Potassium Iodide (KI)
    • 6.2.2. Prussian Blue
    • 6.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 6.2.4. Others
  • 6.3. Market Attractiveness, by Compound

7. Global Anti-radiation Drugs Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Market Value Forecast, by Application, 2017-2031
    • 7.2.1. Acute Radiation Syndrome (ARS)
    • 7.2.2. Cancer Treatment
    • 7.2.3. Radiation Exposure
    • 7.2.4. Others
  • 7.3. Market Attractiveness Analysis, by Application

8. Global Anti-radiation Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Others
  • 8.3. Market Attractiveness Analysis, by Distribution Channel

9. Global Anti-radiation Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Anti-radiation Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Compound, 2017-2031
    • 10.2.1. Potassium Iodide (KI)
    • 10.2.2. Prussian Blue
    • 10.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Acute Radiation Syndrome (ARS)
    • 10.3.2. Cancer Treatment
    • 10.3.3. Radiation Exposure
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Compound
    • 10.6.2. By Application
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Anti-radiation Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Compound, 2017-2031
    • 11.2.1. Potassium Iodide (KI)
    • 11.2.2. Prussian Blue
    • 11.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Acute Radiation Syndrome (ARS)
    • 11.3.2. Cancer Treatment
    • 11.3.3. Radiation Exposure
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Compound
    • 11.6.2. By Application
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Anti-radiation Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Compound, 2017-2031
    • 12.2.1. Potassium Iodide (KI)
    • 12.2.2. Prussian Blue
    • 12.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Acute Radiation Syndrome (ARS)
    • 12.3.2. Cancer Treatment
    • 12.3.3. Radiation Exposure
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Compound
    • 12.6.2. By Application
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Anti-radiation Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Compound, 2017-2031
    • 13.2.1. Potassium Iodide (KI)
    • 13.2.2. Prussian Blue
    • 13.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Acute Radiation Syndrome (ARS)
    • 13.3.2. Cancer Treatment
    • 13.3.3. Radiation Exposure
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Compound
    • 13.6.2. By Application
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Anti-radiation Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Compound, 2017-2031
    • 14.2.1. Potassium Iodide (KI)
    • 14.2.2. Prussian Blue
    • 14.2.3. DTPA (Diethylenetriamine Pentaacetate)
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Acute Radiation Syndrome (ARS)
    • 14.3.2. Cancer Treatment
    • 14.3.3. Radiation Exposure
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Compound
    • 14.6.2. By Application
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. Amgen Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Compound Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Anbex Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Compound Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Arco Pharmaceuticals LLC
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Compound Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
    • 15.3.4. BTG International Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Compound Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Cellphire, Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Compound Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Chrysalis BioTherapeutics, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Compound Portfolio
      • 15.3.6.3. SWOT Analysis
    • 15.3.7. Darnitsa
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Compound Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Strategic Overview
    • 15.3.8. Enzychem Lifesciences Corporation
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Compound Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Strategic Overview
    • 15.3.9. Humanetics Corporation
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Compound Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Mission Pharmacal Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Compound Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Myelo Therapeutics GmbH
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Compound Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Partner Therapeutics
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Compound Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Pluri Inc.
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Compound Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Other Players
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Compound Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 02: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 07: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 11: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 15: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 19: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017-2031
  • Table 23: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Anti-radiation Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
  • Figure 02: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Compound, 2021
  • Figure 03: Global Anti-radiation Drugs Market Value Share, by Compound, 2021
  • Figure 04: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Application, 2021
  • Figure 05: Global Anti-radiation Drugs Market Value Share, by Application, 2021
  • Figure 06: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Distribution Channel, 2021
  • Figure 07: Global Anti-radiation Drugs Market Value Share, by Distribution Channel, 2021
  • Figure 08: Global Anti-radiation Drugs Market Value Share, by Region, 2021
  • Figure 09: Global Anti-radiation Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 11: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Potassium Iodide (KI), 2017-2031
  • Figure 12: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DTPA (Diethylenetriamine Pentaacetate), 2017-2031
  • Figure 13: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prussian Blue, 2017-2031
  • Figure 14: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 15: Global Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 16: Global Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 17: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Acute Radiation Syndrome (ARS), 2017-2031
  • Figure 18: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Treatment, 2017-2031
  • Figure 19: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Exposure, 2017-2031
  • Figure 20: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 21: Global Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 22: Global Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 23: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
  • Figure 24: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
  • Figure 25: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 26: Global Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Global Anti-radiation Drugs Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 28: Global Anti-radiation Drugs Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 29: North America Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 30: North America Anti-radiation Drugs Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 31: North America Anti-radiation Drugs Market Value Share Analysis, by Country, 2017 and 2031
  • Figure 32: North America Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 33: North America Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 34: North America Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 35: North America Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 36: North America Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 37:North America Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 38: Europe Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 39: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 40: Europe Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 41: Europe Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 42: Europe Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 43: Europe Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 44: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 45: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 46: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 47: Asia Pacific Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 48: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 49: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 50: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 51: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 52: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 53: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 54: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 55: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 56: Latin America Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 57: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 58: Latin America Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 59: Latin America Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 60: Latin America Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 61: Latin America Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 62: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 63: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 64: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 65: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 66: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 67: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 68: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031
  • Figure 69: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031
  • Figure 70: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 71: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031
  • Figure 72: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 73: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031